近年来,随着功能因素在肝硬化门脉阻力增加中作用的研究,为血管扩张药物治疗门脉高压提供了依据。钙通道阻滞剂(Calciumchannel blocker,CCB)为一舒血管作用较强的药物,临床上被广泛应用于心血管疾病的治疗,近年来发现其在肝硬化门脉高压治疗方面的应用价值,现就这方面资料作以综述。 1 作用及降低门脉压力现状 1984年Reichen等通过四氯化碳诱发的肝硬化大鼠模型实验,发现异搏停能降低 In recent years, with the functional factors in the cirrhosis of the portal vein resistance increases in the role of vasodilator drugs provide a basis for the treatment of portal hypertension. Calcium channel blocker (Calcium channel blocker, CCB) is a strong vasodilator drugs, clinically widely used in the treatment of cardiovascular disease, in recent years found its value in the treatment of cirrhosis and portal hypertension, and now To summarize this information. 1 role and reduce the status of portal pressure In 1984, Reichen and other carbon tetrachloride-induced liver cirrhosis rat model experiments found that verapamil can be reduced